SuperworthFortrea FTRE
- Market cap
- $2.2B
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 0.8×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $2.7B
- −2% on a year ago
- Net margin
- −3.2%
- Free cash flow yield
- 8.7%
Fortrea trades at 0.8× sales. Revenue was $2.7B over the last twelve months, down 2% on a year earlier with a −3% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $713.8M−6% | $709.7M−7% | $662.1M−5% | $662.4M−9% | $674.9M−5% | $697M−2% | $651.3M−2% | $710.3M+7% | $701.3M+4% | $660.5M−5% | $636.5M−2% | $678.2M−5% | |
| Cost of revenue | $563.8M−5% | $577.9M−4% | $554.2M+2% | $525.3M−8% | $526.6M−7% | $556.1M−4% | $534.8M−4% | $576.8M+10% | $578.6M+10% | $529.4M−5% | $512.9M−4% | $539M−7% |
| Gross profit | $150M−10% | $131.8M−19% | $107.9M−29% | $137.1M−12% | $148.3M−1% | $140.9M+7% | $116.5M+8% | $133.5M−3% | $122.7M−17% | $131.1M−7% | $123.6M+6% | $139.2M+4% |
| SG&A | $106.8M+51% | $126.7M+100% | $120.1M+3% | $156.2M+60% | $136.3M+28% | $148.1M+17% | $121.8M+1% | $124.8M−20% | $106.8M−22% | $103M−31% | $100.5M−18% | $102.1M−18% |
| $10.3M−85% | −$24M | −$37.4M | −$50.9M | −$18M | −$55.6M+132% | −$520.1M+1291% | −$330.3M+549% | −$8.6M−52% | −$13.6M−76% | −$3.4M−99% | $14.8M | |
| Interest expense | $34.6M | $34.5M+17150% | $34.3M+34200% | $45.2M+6357% | $22.4M−35% | $21.9M−37% | $22.3M−35% | $23.3M−49% | $22.6M+1% | $23.2M+6% | $19.1M−14% | $19.3M−17% |
| Pre-tax income | −$21.9M | −$54.7M | −$75.7M | −$88.6M | −$35.8M+64% | −$74.9M+37% | −$548M+624% | −$370.7M+318% | −$28.7M−20% | −$35.6M−53% | −$12.3M−98% | −$1.2M−100% |
| −$5.8M | −$6.1M | $4.1M+173% | $10.7M−8% | −$17.3M+198% | −$1M−84% | $14.9M+263% | $4.2M−61% | −$12.8M−26% | −$3.1M+210% | $11.3M−24% | $12M+186% | |
| Net income | −$14M | −$54.5M | −$101M | −$138.4M | −$27.9M+99% | −$61.2M+12% | −$562.9M+457% | −$374.9M+171% | −$15.9M−43% | −$32.5M−47% | −$23.6M−96% | −$13.2M−97% |
| −$0.16 | −$0.61 | −$1.13 | −$1.55 | −$0.31+94% | −$0.68+12% | −$6.25+453% | −$4.14+167% | −$0.17−45% | n/a | −$0.25−96% | −$0.14−97% | |
| 88.8M+0% | 88.8M+0% | 89.2M+1% | 89.4M+1% | 89.6M+1% | 89.8M+1% | 90.1M+1% | 90.6M+1% | n/a | n/a | 93.6M+4% | 94.8M+5% |
Revenue: Q1 FY22: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY22: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY22: 6 months less the 3 months printed beside them. 17 periods, Q2 FY22 to Q2 FY26: not printed by the filing, worked out from its own lines.
SG&A: Q1 FY22: 6 months less the 3 months printed beside them.
Operating income: Q1 FY22: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY22: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY22: 6 months less the 3 months printed beside them.
Income tax: Q1 FY22: 6 months less the 3 months printed beside them.
Net income: Q1 FY22: 6 months less the 3 months printed beside them.
EPS, diluted: 4 periods, Q1 FY22 to Q4 FY24: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY22 and Q1 FY23: share-days: the 6-month average less the second quarter's. Q4 FY22: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY23 and Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Diagnostics & Research nearest Fortrea's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| FTREFortrea | $2.2B | n/m | n/a | 0.8× | −2% | −3.2% | |
| CDNACareDx | $3.6B | 33.4× | 19.1× | 7.8× | +34% | 24.2% | |
| VCYTVeracyte | $3.9B | 34.2× | 66.8× | 6.9× | +17% | 20.4% | |
| BLLNBillionToOne | $5.1B | 166× | 151× | 12.8× | +90% | 9.5% | |
| LNTHLantheus | $6.5B | 24.2× | 24.0× | 4.2× | +2% | 17.7% | |
| CAICaris Life Sciences | $9B | 86.5× | 73.7× | 9.1× | +85% | 10.6% | |
| BIOBio-Rad Laboratories | $9.9B | 44.8× | 30.8× | 3.8× | +1% | 8.6% | |
| NRCNRC Health | $485.1M | 87.7× | 35.1× | 3.5× | −0% | 4.2% | |
| RVTYRevvity | $17.7B | 75.6× | 34.8× | 6.1× | +4% | 8.2% | |
| MEDPMedpace | $18.7B | 39.2× | 34.5× | 6.7× | +25% | 17.7% | |
| Peer median | $6.5B | 44.8× | 34.8× | 6.7× | +17% | 10.6% |
More on Fortrea
Each number over time
- PE ratio
- Price to sales ratio
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #1of 28Diagnostics and research stocks with the highest free cash flow yield
- #7of 61Diagnostics and research stocks with the lowest price to sales ratio
Its groups
About
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .